# NADIR (NCT04037254)

> Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

No report yet. It can be ordered.

- Drugs tested: niraparib
- Indication: high-risk prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04037254
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: NRG Oncology
- Conditions: Prostate Adenocarcinoma; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
- Interventions: Gonadotrophin Releasing Hormone; Intensity-Modulated Radiation Therapy; Niraparib
- Enrollment: 22
- Primary outcome: Number of Participants Disease-free Until Completion of Treatment (2 Years From Start of ADT)

## Indexed commentary on NADIR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nadir-nct04037254